Oncologix Tech

Oncologix Tech FCF Margin

Delisted·Sep 9, 2026

The Free Cash Flow Margin of Oncologix Tech (OCLG) as of Oct 28, 2026 is -0.88 %. In the previous year, Free Cash Flow Margin was 8.57 % — a change of -110.28% (lower).

FCF Margin

-0.88 %

YoY

-110.28%

Last updated:

Free Cash Flow Margin of Oncologix Tech is 2017 -0.88 % . Free Cash Flow Margin of Oncologix Tech was 2016 8.57 % . It decreases by -110.28% lower compared to the previous year.

The Oncologix Tech FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2014
-17.16 USD
Jan 1, 2015
-7.34 USD
Jan 1, 2016
8.57 USD
Jan 1, 2017
-0.88 USD
The Oncologix Tech FCF Margin history
YEARFCF MarginYoY
-0.88 %-110.28%
8.57 %-216.82%
-7.34 %-57.22%
-17.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oncologix Tech Stock analysis

What does Oncologix Tech do? Oncologix Tech, Inc. generates revenue through the operation and manufacture of medical device products. The company collaborates with manufacturers and stakeholders in the United States and South Korea to execute agreements with partners, customers, vendors, and manufacturers. It reviews licenses and sublicense agreements with potential licensors and conducts research and due diligence on potential partners, joint-ventures, and acquisitions in the biotech industry. Oncologix Tech, Inc. seeks additional acquisitions of diagnostic and biotechnology opportunities to expand its portfolio. The firm's primary customers include partners, customers, vendors, and manufacturers within the medical device and biotech sectors. It targets opportunities in diagnostic and biotechnology fields through strategic acquisitions and partnerships. Oncologix Tech, Inc. focuses on executing agreements and conducting due diligence to secure new ventures in the biotech industry. Oncologix Tech, Inc. operates as a medical holding company with a focus on medical device products. It engages in reviewing licenses and sublicense agreements and conducts research on potential acquisitions. The company aims to expand its operations by acquiring diagnostic and biotechnology opportunities in the market. Oncologix Tech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oncologix Tech stock

Free Cash Flow Margin of Oncologix Tech is -0.88 % in 2017.

Free Cash Flow Margin of Oncologix Tech changed from 8.57 % to -0.88 %, representing a -110.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Oncologix Tech since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Oncologix Tech with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Oncologix Tech

All Key Metrics — Oncologix Tech